![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Switching to dolutegravir/lamivudine two-drug regimen:
durability and virologic outcomes in
routine U.S. clinical care
|
|
|
AIDS 2022 July 29- Aug 1 Montreal
Gerald Pierone1, Laurence Brunet2, Jennifer S Fusco2, Cassidy Henegar3, Supriya Sarkar3, Jean van Wyk4, Vani Vannappagari3, Gregory P Fusco2
1 Whole Family Health Center, Vero Beach, FL, USA; 2 Epividian, Durham, NC, USA; 3 ViiV Healthcare, Research Triangle Park, NC, USA; 4 ViiV Healthcare, Brentford, UK
![0804221copy](../images/080522/080522-11/0804221copy.gif)
![0804222copy](../images/080522/080522-11/0804222copy.gif)
![0804223copy](../images/080522/080522-11/0804223copy.gif)
![0804224copy](../images/080522/080522-11/0804224copy.gif)
![0804225copy](../images/080522/080522-11/0804225copy.gif)
![0804226copy](../images/080522/080522-11/0804226copy.gif)
![0804227copy](../images/080522/080522-11/0804227copy.gif)
![0804228copy](../images/080522/080522-11/0804228copy.gif)
![0804229copy](../images/080522/080522-11/0804229copy.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|